We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Device Facilitates ECG Collection in Clinical Trials

By HospiMedica International staff writers
Posted on 31 Mar 2011
A portable device with an intuitive, single-button design and a high level of automation aids in centralized electrocardiogram (ECG) collection for pharmaceutical clinical trials.

The Spaulding IQ foolproof ECG device is a handheld device, which reduces errors and allow for data capture in less time and at a lower cost than conventional ECG devices. More...
The Spaulding IQ captures the subject's voiceprint as a means of biometric identification, together with five minutes of ECG recording. Directly after recording, the ECG data, demographic, and visit information are sent to the Spaulding Clinical ECG Information System. The automation and integration requires virtually no involvement from the site personnel.

The IQ is a proprietary device of Spaulding Clinical Research (West Bend, WI, USA), which provides onsite and integrated ECG analysis via automatic, semiautomatic, and manual reading options, offering flexibility in securing quality clinical ECG data. Pharmaceutical companies receive near real-time access to their results through an advanced clinical trial management system (ALPHADAS). All lab results are electronic and can be returned within eight hours of collection. Site-to-submission reporting capabilities feature secure online data results for turnkey project management.

"The greatest value of this new process is that it makes it logistically and financially feasible to collect very high-quality, centralized ECG information in virtually all clinical trials,” said Jay Mason, MD, Chief Medical Officer of Spaulding Clinical Research. "This will greatly improve subject safety during trials and drug safety in the marketplace. Pharmaceutical sponsors will gain the ability to make earlier, better-informed drug development decisions.”

Related Links:

Spaulding Clinical Research




New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Fetal Monitor
BT-380
New
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.